Chavassieux P, Chapurlat R, Portero-Muzy N, et al. - In postmenopausal women with osteoporosis, researchers described the impact of romosozumab on bone tissue by bone histomorphometry early in treatment at 2 months, and assessed in another patient cohort the evolution of these effects after 12 months of romosozumab administration. Transiliac bone biopsies were performed for 107 patients at either month 2 (n = 34) or month 12 (n = 73) with a 7.5-mm inner diameter trephine. According to findings, romosozumab resulted in an early and transient increase in bone formation, but a persistent reduction in bone resorption. Eventually, antiresorptive action led to lower bone turnover. This effect led to significant bone mass increases and improved microarchitecture.